Research use only.  Educational reference. Not medical advice. Not for human consumption.
šŸ”§ Tissue Repair Peptide

TB-500 (Thymosin Beta-4 Fragment) (20 mg Vial) Dosage Protocol

TB-500 is a synthetic fragment of Thymosin Beta-4, a regenerative peptide found in nearly all human cell types. It is studied for tissue repair, wound healing, and cardiac regeneration. This page covers the 20 mg vial.

⚔ Quickstart Highlights

Vial size
20 mg
Reconstitution
3 mL BAC water → 6.67 mg/mL
1 U-100 unit =
66.7 mcg
Frequency
Once daily

Dosing & Reconstitution Guide

Route: Subcutaneous  |  Frequency: Once daily  |  Half-life: ~60 minutes

Standard Approach (3 mL = 6.67 mg/mL)

Reconstituting with 3 mL bacteriostatic water produces a concentration of 6.67 mg/mL. Volume per dose changes with concentration; mg dose itself does not change between vial sizes.

Phase / ProtocolDoseU-100 UnitsVolumeDoses per vial
Weeks 1–2 (titration)500 mcg7.5 units0.075 mL40 doses
Weeks 3–4600 mcg9 units0.090 mL33 doses
Weeks 5–8750 mcg11.2 units0.11 mL26 doses
Weeks 9–12 (target)1 mg15 units0.15 mL20 doses

Reconstitution Steps

  1. Wipe the vial stopper and BAC water vial with alcohol; let dry.
  2. Draw 3 mL of bacteriostatic water into a sterile syringe.
  3. Inject slowly down the inside glass wall of the peptide vial. Do not aim at the powder.
  4. Gently swirl until fully dissolved. Do not shake.
  5. Label with reconstitution date. Refrigerate at 2–8°C; use within 30 days.

Supplies Needed

Estimates for an 8-week and 12-week cycle at 750 mcg per dose, once daily (7 doses/week).

Item8-Week Cycle12-Week Cycle
TB-500 (Thymosin Beta-4 Fragment) (20 mg) vials3 vials4 vials
Insulin syringes (U-100)5684
Bacteriostatic water (10 mL)1 Ɨ 10 mL2 Ɨ 10 mL
Alcohol swabs1 Ɨ 100-pack2 Ɨ 100-pack

Protocol Overview

TB-500 protocols use gradual daily titration to a steady-state dose. Total weekly dose averages ~5 mg, consistent with the most-cited research protocols.

The peptide is particularly studied for connective-tissue injuries (tendons, ligaments, fascia) and in stacked protocols with BPC-157 (Wolverine Blend) where the two work via complementary mechanisms.

Cycle length: 8–12-week daily protocol is the standard pattern. Some users extend to 16 weeks for chronic injury support.

Note on athletic competition: TB-500 is on the WADA prohibited list. Out-of-competition detection windows exist.

Dosing Protocol

Daily titration approach (subcutaneous):

Cycle structure: 8–12 weeks daily → 4-week break. Extend to 16 weeks if research goals require.

Weekly total: ~3.5–7 mg/week (averages 5 mg/week across the cycle).

Stacking: Wolverine Blend (BPC-157 + TB-500) is the most common research protocol — each peptide hits different aspects of soft-tissue repair.

Timing: Once per day at a consistent time; rotate injection sites.

Storage Instructions

StateTemperatureDuration
Lyophilizedāˆ’20°C (āˆ’4°F)Up to 24 months, dry & dark
Reconstituted2–8°C (35–46°F)Up to 30 days, protect from light

Important Notes

⚠ Research Use Only: TB-500 is investigational; most data preclinical. WADA prohibited list for competitive athletes.

How This Works

TB-500 is a synthetic fragment of Thymosin Beta-4 (Tβ4), a 43-amino-acid protein found in virtually every human cell and concentrated in platelets and wound fluid. The active TB-500 region binds G-actin and regulates cytoskeletal organization and cell motility.

It promotes endothelial cell migration, accelerates wound closure, supports cardiomyocyte recovery after infarction, reduces fibrosis, and modulates inflammatory cytokine release. The peptide also up-regulates laminin-5 and integrin-linked kinase, both involved in cell-matrix adhesion during repair.

Potential Benefits & Side Effects

Potential Benefits

Side Effect Profile

Lifestyle Factors

Injection Technique

References

1
Goldstein AL et al. 'Thymosin β4 and the diabetic wound' — Ann NY Acad Sci, 2007 View source ↗
2
Bock-Marquette I et al. 'Thymosin β4 and cardiac repair' — Nature, 2004 View source ↗
3
Crockford D et al. 'Thymosin β4 clinical applications' — Ann NY Acad Sci, 2010 View source ↗